Recce Pharmaceuticals (ASX:RCE) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

RCE 주식 개요

호주, 영국, 미국에서 합성 항감염제를 발견, 개발 및 상용화하는 Recce Pharmaceuticals Ltd.

RCE 기본 분석
눈송이 점수
가치 평가	0/6
미래 성장	0/6
과거 실적	0/6
재무 상태	2/6
배당금	0/6

보상

위험 분석

마이너스 주주 지분

수익은 향후 3년간 연평균 56.3% 씩 감소할 것으로 예상됩니다.

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.

지난 1년 동안 주주가 희석되었습니다.

+ 2 더 많은 위험

Recce Pharmaceuticals Ltd 경쟁사

Percheron Therapeutics

ASX:PER

AU$90.2m

Argenica Therapeutics

ASX:AGN

AU$87.1m

Vita Life Sciences

ASX:VLS

AU$126.1m

Vitura Health

ASX:VIT

AU$42.0m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Recce Pharmaceuticals
과거 주가
현재 주가	AU$0.51
52주 최고치	AU$0.69
52주 최저치	AU$0.41
베타	1.05
11개월 변경	2.02%
3개월 변경 사항	5.21%
1년 변경 사항	13.48%
33년 변화	-47.12%
5년 변화	60.32%
IPO 이후 변화	68.33%

최근 뉴스 및 업데이트

Recent updates

We Think Shareholders Are Less Likely To Approve A Pay Rise For Recce Pharmaceuticals Ltd's (ASX:RCE) CEO For Now

Nov 01

Here's Why We're Watching Recce Pharmaceuticals' (ASX:RCE) Cash Burn Situation

Feb 13

We're Hopeful That Recce Pharmaceuticals (ASX:RCE) Will Use Its Cash Wisely

Jul 28

Recce Pharmaceuticals (ASX:RCE) Is In A Good Position To Deliver On Growth Plans

Dec 07

We're Hopeful That Recce Pharmaceuticals (ASX:RCE) Will Use Its Cash Wisely

Aug 03

Recce Pharmaceuticals (ASX:RCE) Is In A Good Position To Deliver On Growth Plans

Mar 08

Need To Know: Recce Pharmaceuticals Ltd (ASX:RCE) Insiders Have Been Selling Shares

Feb 01

Could The Recce Pharmaceuticals Ltd (ASX:RCE) Ownership Structure Tell Us Something Useful?

Dec 09

주주 수익률

	RCE	AU Pharmaceuticals	AU 마켓
7D	-2.9%	1.6%	1.7%
1Y	13.5%	98.7%	17.2%

수익률 대 산업: RCE 지난 1년 동안 61.8 %를 반환한 Australian Pharmaceuticals 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: RCE 지난 1년 동안 17.2 %를 반환한 Australian 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is RCE's price volatile compared to industry and market?
RCE volatility
RCE Average Weekly Movement	7.5%
Pharmaceuticals Industry Average Movement	10.2%
Market Average Movement	9.0%
10% most volatile stocks in AU Market	17.4%
10% least volatile stocks in AU Market	3.6%

안정적인 주가: RCE 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.

시간에 따른 변동성: RCE 의 주간 변동성( 11% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
2007	n/a	James Graham	www.recce.com.au

호주, 영국, 미국에서 합성 항감염제를 발견, 개발 및 상용화하는 Recce Pharmaceuticals Ltd. 주요 후보 물질은 슈퍼버그 형태를 포함하여 대장균과 황색포도상구균에서 유래한 혈액 감염 및 패혈증 치료를 위한 RECCE 327(R327)입니다. 또한 바이러스 감염에 대한 합성 항감염제인 RECCE 529와 경구용으로 제조된 합성 폴리머 항생제인 RECCE 435도 개발하고 있습니다.

Recce Pharmaceuticals Ltd 기본 사항 요약

Recce Pharmaceuticals 의 수익과 매출은 시가총액과 어떻게 비교하나요?
RCE 기본 통계
시가총액	AU$116.96m
수익(TTM)	-AU$17.66m
수익(TTM)	AU$5.03m

23.3x

P/S 비율

-6.6x

P/E 비율

RCE 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
RCE 손익 계산서(TTM)
수익	AU$5.03m
수익 비용	AU$7.22m
총 이익	-AU$2.19m
기타 비용	AU$15.47m
수익	-AU$17.66m

최근 보고된 수익

Jun 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-0.076
총 마진	-43.52%
순이익 마진	-351.24%
부채/자본 비율	-101.7%

RCE 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

RCE 주식 개요

보상

위험 분석

Recce Pharmaceuticals Ltd 경쟁사

ASX:PER

AU$90.2m

ASX:AGN

AU$87.1m

ASX:VLS

AU$126.1m

ASX:VIT

AU$42.0m

가격 내역 및 성능

최근 뉴스 및 업데이트

Recce Pharmaceuticals Ltd, Annual General Meeting, Nov 06, 2024

New major risk - Revenue and earnings growth

Recce Pharmaceuticals Announces Positive Preclinical Efficacy Data Against WHO Priority Pathogen Acinetobacter Baumannii

Recce Pharmaceuticals Ltd has filed a Follow-on Equity Offering in the amount of AUD 2 million.

Recce Pharmaceuticals Reports Positive Data from Phase I/Ii Urinary Tract Infection (Uti) / Urosepsis Rapid Infusion Trial of Recce® 327

Recce Pharmaceuticals Ltd. Receives Ethics Approval to Broaden RECCE 327 Gel Trials Across All Topical Bacterial Skin Infections

Recent updates

Recce Pharmaceuticals Ltd, Annual General Meeting, Nov 06, 2024

New major risk - Revenue and earnings growth

Recce Pharmaceuticals Announces Positive Preclinical Efficacy Data Against WHO Priority Pathogen Acinetobacter Baumannii

Recce Pharmaceuticals Ltd has filed a Follow-on Equity Offering in the amount of AUD 2 million.

Recce Pharmaceuticals Reports Positive Data from Phase I/Ii Urinary Tract Infection (Uti) / Urosepsis Rapid Infusion Trial of Recce® 327

Recce Pharmaceuticals Ltd. Receives Ethics Approval to Broaden RECCE 327 Gel Trials Across All Topical Bacterial Skin Infections

Recce Pharmaceuticals Announces Addition of RECCE® 327 to the World Health Organization’S List of Antibacterial Products in Clinical Development

Recce Pharmaceuticals Ltd Doses First Participants in Next Cohort of Phase I/II Urinary Tract Infections and Urosepsis Rapid Infusion Clinical Trial

Recce Pharmaceuticals Reports Positive Preclinical Data of Recce® 327 in Lung Infection Pilot Study

Recce Pharmaceuticals Ltd Receives New Patent in China for RECCE Anti-Infectives from China National Intellectual Property Administration

New major risk - Revenue and earnings growth

Recce Pharmaceuticals Ltd. Announces Safety Committee Approves High Dose of 4,000mg in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis

Recce Pharmaceuticals Ltd. Completes 5,000 RECCE 327 Doses Week Under Good Manufacturing Practice

Recce Pharmaceuticals Ltd Receives New Patent in Israel for Recce Anti-Infectives

New major risk - Revenue and earnings growth

Recce Pharmaceuticals Completes Dosing Cohort in Phase I/II Trial of Recce® 327 for Urinary Tract Infections and Urosepsis

Recce Pharmaceuticals Ltd Doses Next Cohort in Phase I/II Trial of RECCE 327 for Urinary Tract Infections and Urosepsis

Recce Pharmaceuticals Reports Positive Phase I/II Trial Results of RECCE 327 for the Treatment of Diabetic Foot Infections

Recce Pharmaceuticals Receives Ausindustry Advanced Overseas Finding for Synthetic Anti-Infective Research & Development Program

Recce Pharmaceuticals Ltd Reports Positive Preclinical Data of RECCE 327 Against Gonorrhoeae

Recce Pharmaceuticals Limited Announces Canadian Patent Granted for Recce® Anti-Infectives

Recce Pharmaceuticals Ltd Completes Dosing First Subjects at 15-Minute Infusion Rate in a Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis

We Think Shareholders Are Less Likely To Approve A Pay Rise For Recce Pharmaceuticals Ltd's (ASX:RCE) CEO For Now

Recce Pharmaceuticals Ltd Announces Safety Committee Approves Faster Infusion Rate in Phase I/Ii Trial of Recce® 327 for Urinary Tract Infections and Urosepsis

Recce Pharmaceuticals Ltd has completed a Follow-on Equity Offering in the amount of AUD 3.022261 million.

Recce Pharmaceuticals Ltd has completed a Follow-on Equity Offering in the amount of AUD 3.022261 million.

Recce Pharmaceuticals Ltd has completed a Follow-on Equity Offering in the amount of AUD 2.715261 million.

Recce Pharmaceuticals Completes Dosing in Phase I/II Clinical Trial of Recce® 327 for Urinary Tract Infections

Recce Pharmaceuticals Ltd, Annual General Meeting, Nov 08, 2023

New minor risk - Shareholder dilution

Recce Pharmaceuticals Ltd Provides Additional Positive Update on Patients Treated Under "Special Access Scheme"

Recce Pharmaceuticals Ltd Announces Safety Committee Approves Next Dose of Recce®? 327 At 3,000Mg in Phase I/Iiuti/Urosepsis Rapid Infusion Clinical Trial

New minor risk - Financial data availability

Recce Pharmaceuticals Ltd Doses Patients in Phase I/II Clinical Trial of Recce 327 for Diabetic Foot Infections

Recce Pharmaceuticals Ltd. Completes Stage 1 Data Analysis of Phase I/II Clinical Trial for the Treatment of Burn Wound Infections

Recce Pharmaceuticals Ltd Provides Positive Update on Patients Treated with RECCE®? 327 Under "Special Access Scheme"

Recce Pharmaceuticals Completes First Cohort Dosing of Phase l/ll UTI Rapid Infusion Clinical Trial at Scientia Clinical Research

Recce Pharmaceuticals Achieves Positive Phase I Clinical Trial Data of RECCE(R) 327 as an Intravenous Infusion Formulation

Recce Pharmaceuticals Limited Announces First Cohort Dosed in Recce®? 327 Rapid Infusion Phase I/II Urinary Tract Infection (UTI) Clinical Trial

CEO, MD & Executive Director recently bought AU$308k worth of stock

Here's Why We're Watching Recce Pharmaceuticals' (ASX:RCE) Cash Burn Situation

Recce Pharmaceuticals to Be Granted Anti-Viral Patent in Australia for RECCE® Anti-Infectives

Recce Pharmaceuticals Limited Announces Australian Patent Office Issued Notification of Intent to Grant Recce's Patent Family 3

Recce Pharmaceuticals Ltd Receives Ethics Approval to Start Phase 1/2 Study Evaluating RECCE(R) 327 in Patients with Diabetic Foot Infections

Recce Pharmaceuticals Ltd Receives Ethics Approval to Start Phase I/II Diabetic Foot Ulcer Study

Less than half of directors are independent

Recce Pharmaceuticals Ltd Provides RECCE 327 SARS-CoV-2 Study Update

Recce Pharmaceuticals Ltd Provides RECCE 327 SARS-CoV-2 Study Update

Recce Pharmaceuticals Announces Expansion and Acceleration of Clinical Programs

Recce Pharmaceuticals Ltd, Annual General Meeting, Nov 14, 2022

Recce Pharmaceuticals Appoints Alistair McKeough to Its Board of Directors and Maggie Niewidok as Company Secretary

Recce Announces Management Changes

Recce Pharmaceuticals Ltd Reports Positive Safety Data from Seventh Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327

We're Hopeful That Recce Pharmaceuticals (ASX:RCE) Will Use Its Cash Wisely

Recce Pharmaceuticals Ltd announces Positive Safety Data from Fifth Cohort of Phase I Clinical Trial of RECCE 327 and Initiates Sixth Cohort At 4,000Mg

Less than half of directors are independent

Recce Pharmaceuticals Ltd Announces Anti-Viral Patent Granted in Hong Kong

Recce Pharmaceuticals Ltd Announces Safety Committee Clears Next Dose in Phase I Study of Recce® 327

Recce Pharmaceuticals Ltd Announces Positive Safety Data from Second Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327